In the second part of our cell therapy series this week, we take on three quite different issues.
These include the following:
- A new dual CAR in development
- Where cell therapy may be heading and how to address the limitations
- The Cellectis CS–1/SLAMF7 clinical hold
Not all CAR T cell therapies are going to end up as a bridge to transplant – some of them are clearly intended to be more efficacious than their predecessors – but along the way the trials, tribulations and clinical challenges continue apace.
These are all meaty topics to consider, so with out much further ado, let’s roll…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from recent events, subscribers can log-in or you can click to gain access to BSB Premium Content.
We have been following the progress of various classes of molecules in the myeloma space here on BSB since 2010. These include traditional approaches (e.g. HSCT and proteasome inhibitors/IMiDs and various antibodies or ADCs), as well as immunotherapy (checkpoint blockade, CAR T cell therapy, oncolytic viruses etc).
Brick Lane Grafitti
There’s much going on in this space and it’s not only becoming extremely crowded and competitive (akin to 1L NSCLC), but there is a gradual trend towards convergence on many fronts, be they targets or modalities.
In our latest look at the myeloma space, we focus on several key areas of development – antibodies, CARs, and also highlight a new target that may be of interest…
To learn more from our latest biotech and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.